This study states that Leuprolide Acetate has been utilized for quite a long time to treat hormone‐sensitive conditions like prostate disease and endometriosis. In creature models of AD, leuprolide jelly discernment and diminishes amyloid testimony and tau phosphorylation by diminishing degrees of Luteinizing Hormone. A subgroup investigation of an earlier human preliminary (Bowen, 2016) showed that leuprolide profited insight and capacity in ladies who were likewise taking donepezil. Here we depict a continuous clinical preliminary of leuprolide to affirm and expand these outcomes.
A three‐site, double‐blind, randomized preliminary of Leuprolide Acetate (22.5 mg/12 weeks) contrasted with fake treatment with assess the progressions more than 48 weeks in insight, work, mind MRI measures (volume, hippocampal blood stream) and blood biomarkers of irritation in ladies (n=150) with mild‐moderate AD who are likewise taking a steady portion of donepezil. By re‐purposing a current medicine, in blend with a momentum AD treatment, we will actually want to expand upon broad past innovative work endeavors, decreasing the time period and expenses of making this promising treatment accessible to patients with AD. Re‐purposing a current medication probably addresses the lone practical alternative for meeting the HHS objective to Forestall and Effectively Treat Alzheimer’s Disease and Related Dementias by 2025.
Reference link- https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.038780
